Review Article | Published:

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Nature Reviews Cancer volume 17, pages 286301 (2017) | Download Citation

Abstract

Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous, genetic drivers of tumorigenesis have led to the development of clinically important targeted agents that result in profound, but often not durable, tumour responses in genetically defined patient populations. In the second parallel approach, exploration of the mechanisms of protective tumour immunity has provided several therapeutic strategies — most notably the 'immune checkpoint' antibodies that reverse the negative regulators of T cell function — that accomplish durable clinical responses in subsets of patients with various tumour types. The integration of these potentially complementary research fields provides new opportunities to improve cancer treatments. Targeted and immune-based therapies have already transformed the standard-of-care for several malignancies. However, additional insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies that increase the rate of complete and durable clinical response in patients.

Key points

  • The largely independent research fields of targeted and immune-based cancer therapies are integrating.

  • Research is focused on understanding the impact that targeted and conventional cancer therapies (chemotherapy and radiation) have on the generation of an antitumour immune response. Protective tumour immunity is thought to require innate immune stimulation, a robust cytotoxic T cell response and overcoming an immunosuppressive tumour microenvironment.

  • Insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies that increase the rate of complete and durable clinical responses in patients.

  • Immune checkpoint inhibitors are emerging as a backbone of cancer therapy and are being combined in clinical trials with many targeted agents.

  • Key future challenges to developing rational combinations include continuing to understand the impact that all cancer therapeutics have on patients' immune systems, optimizing the therapeutic window of treatment through appropriate dosing and temporal sequencing, and prioritizing the rapidly growing number of combination therapy trials.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251–2259 (2010).

  2. 2.

    et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J. Clin. Oncol. 34, 871–878 (2016).

  3. 3.

    et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984–993 (2016).

  4. 4.

    et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).

  5. 5.

    et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).

  6. 6.

    & The future of immune checkpoint therapy. Science 348, 56–61 (2015).

  7. 7.

    , & Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

  8. 8.

    The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am. J. Med. Sci. 105, 487–511 (1893).

  9. 9.

    , & Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).

  10. 10.

    & Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

  11. 11.

    et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).

  12. 12.

    , & Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561–584 (2015).

  13. 13.

    , & Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566–581 (2016).

  14. 14.

    & The odds of immunotherapy success. Science 350, 158–159 (2015).

  15. 15.

    et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).

  16. 16.

    , & Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180–183 (1976).

  17. 17.

    et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204, 1441–1451 (2007).

  18. 18.

    & Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147, 1314–1333 (1978).

  19. 19.

    et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 50, 714–721 (2004).

  20. 20.

    et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18, 6748–6757 (2012).

  21. 21.

    et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13, 7119–7125 (2007).

  22. 22.

    et al. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin. Cancer Res. 20, 3683–3691 (2014).

  23. 23.

    US National Library of Medicine. ClinicalTrials.gov (2014).

  24. 24.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  25. 25.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  26. 26.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  27. 27.

    & STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).

  28. 28.

    et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015). This paper demonstrates that direct activation of STING through intratumoural administration of selective agonists induces regression of established tumours in mice, generates systemic immune responses capable of rejecting distant metastases (abscopal effect) and results in an antitumour immune memory response.

  29. 29.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  30. 30.

    et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death Differ. 21, 1825–1837 (2014).

  31. 31.

    et al. 5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14, 1256–1263 (2008).

  32. 32.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  33. 33.

    et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119, 2399–2411 (2009).

  34. 34.

    et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 44, 2850–2859 (2007).

  35. 35.

    & Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012).

  36. 36.

    , , & How do tumor cells respond to HDAC inhibition? FEBS J. 283, 4032–4046 (2016).

  37. 37.

    et al. Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: a perfect combination for cancer therapy. Adv. Cancer Res. 130, 55–111 (2016).

  38. 38.

    , & Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 8, 705–719 (2016).

  39. 39.

    , & The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology 3, e27414 (2014).

  40. 40.

    et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774–11779 (2014).

  41. 41.

    & Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 1, 948–950 (2012).

  42. 42.

    et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. Mol. Pharmacol. 65, 18–27 (2004).

  43. 43.

    et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc. Natl Acad. Sci. USA 96, 14007–14012 (1999).

  44. 44.

    et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587–598 (2014).

  45. 45.

    et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunol. Res. 3, 1030–1041 (2015).

  46. 46.

    et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015). This paper illustrates that, in ovarian cancer, DNMT inhibitors can upregulate hypermethylated ERVs, which activate an immune signalling response through the viral defence pathway. Additionally, in patients with melanoma treated with immune checkpoint inhibitors, a high viral defence signature is associated with durable clinical response, suggesting that DNMT inhibitors may sensitize patients to treatment with immunotherapy.

  47. 47.

    et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015). This paper demonstrates that the DNMT inhibitor azacitidine induces dsRNAs derived, in part, from ERVs that activate the mitochondrial antiviral RNA recognition pathway to produce an antitumour immune response.

  48. 48.

    & Endogenous retroviruses: acquisition, amplification and taming of genome invaders. Curr. Opin. Virol. 3, 646–656 (2013).

  49. 49.

    & Immune responses to endogenous retroelements: taking the bad with the good. Nat. Rev. Immunol. 16, 207–219 (2016).

  50. 50.

    , & Long terminal repeats: from parasitic elements to building blocks of the transcriptional regulatory repertoire. Mol. Cell 62, 766–776 (2016).

  51. 51.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  52. 52.

    US National Library of Medicine. ClinicalTrials.gov (2015).

  53. 53.

    & The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).

  54. 54.

    et al. PRC2 epigenetically silences TH1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 76, 275–282 (2016).

  55. 55.

    et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249–253 (2015). This paper demonstrates that, in ovarian cancer mouse models, inhibition of EZH2 or DNMT1 reverses the repression of TH1-type chemokines CXCL9 and CXCL10, increases T cell infiltrates into tumours and sensitizes to anti-PDL1 therapy.

  56. 56.

    & Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).

  57. 57.

    Epizyme (2016). Epizyme initiates collaboration on combination trial of tazemetostat and Tecentriq (atezolizumab) for treatment of non-Hodgkin lymphoma. (2016).

  58. 58.

    et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22, 246–258 (2012).

  59. 59.

    et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).

  60. 60.

    et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473–487 (2012).

  61. 61.

    et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605–611 (2012).

  62. 62.

    The T-cell-receptor signaling network. J. Cell Sci. 122, 1269–1273 (2009).

  63. 63.

    et al. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol. 160, 4175–4181 (1998).

  64. 64.

    , , , & The Erk2 MAPK regulates CD8 T cell proliferation and survival. J. Immunol. 181, 7617–7629 (2008).

  65. 65.

    , , & MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J. Biol. Chem. 276, 14784–14790 (2001).

  66. 66.

    et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21, 1639–1651 (2015).

  67. 67.

    et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016). This paper demonstrates that, although inhibition of MEK blocks naive CD8+ T cell priming in the lymph node, in the TME, MEK inhibition increases antigen-specific CD8+ T cells, protects TILs from death and combines with anti-PDL1 therapy to generate durable tumour regression in mouse models.

  68. 68.

    et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J. Clin. Oncol. 34, abstr. 3502 (2016).

  69. 69.

    , , , & Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365–1366 (2013). This letter outlines hepatic adverse events in a clinical study evaluating the concurrent use of the BRAF inhibitor vemurafenib and the CTLA4 inhibitor ipilimumab, highlighting the dosing and sequencing challenges of combining targeted and immune-based therapies.

  70. 70.

    & All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front. Immunol. 3, 312 (2012).

  71. 71.

    & Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 36, 13–20 (2015).

  72. 72.

    et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016).

  73. 73.

    et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6598–6602 (2006).

  74. 74.

    , , , & The PI3K p110δ regulates expression of CD38 on regulatory T cells. PLoS ONE 6, e17359 (2011).

  75. 75.

    et al. The p110δ isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J. Immunol. 183, 1921–1933 (2009).

  76. 76.

    et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014). This paper demonstrates that inactivation of p110δ, the catalytic subunit of PI3Kδ, in Treg cells inhibits their suppressive function and stimulates CD8+ cytotoxic T cells to induce tumour regression.

  77. 77.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  78. 78.

    et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).

  79. 79.

    et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008–1018 (2014).

  80. 80.

    , & TOR in the immune system. Curr. Opin. Cell Biol. 23, 707–715 (2011).

  81. 81.

    et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112 (2009).

  82. 82.

    , , , & Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer 104, 643–652 (2011).

  83. 83.

    et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 71, 4074–4084 (2011).

  84. 84.

    et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929–941 (2010).

  85. 85.

    et al. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J. Immunol. 186, 2809–2818 (2011).

  86. 86.

    et al. mTOR inhibition improves immune function in the elderly. Sci. Transl Med. 6, 268ra179 (2014).

  87. 87.

    Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876–885 (2005).

  88. 88.

    et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J. Exp. Med. 207, 2195–2206 (2010).

  89. 89.

    & (Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways. Cell Cycle 7, 1511–1521 (2008).

  90. 90.

    , , , & Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol. Immunother. 62, 321–335 (2013).

  91. 91.

    et al. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood 123, 659–668 (2014).

  92. 92.

    , & Tec family kinases in inflammation and disease. Int. Rev. Immunol. 31, 87–103 (2012).

  93. 93.

    et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355–358 (1993).

  94. 94.

    et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119, 3744–3756 (2012).

  95. 95.

    , & Targeting Bruton's tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14, 219–232 (2014).

  96. 96.

    et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539–2549 (2013).

  97. 97.

    & Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 3, 757–769 (1995).

  98. 98.

    , , & T-Cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb. Perspect. Biol. 2, a002287 (2010).

  99. 99.

    et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity 11, 399–409 (1999).

  100. 100.

    et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl Acad. Sci. USA 112, E966–E972 (2015). This paper demonstrates that ibrutinib, an inhibitor of the TEC family members BTK and ITK, in combination with PDL1 inhibition suppresses tumour growth in mouse models of lymphoma that are insensitive to ibrutinib alone and in solid tumours. These data suggest that this combination can be used clinically in tumours other than lymphoma.

  101. 101.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  102. 102.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  103. 103.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  104. 104.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  105. 105.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  106. 106.

    , & Regulation of NF-κB-dependent lymphocyte activation and development by paracaspase. Science 302, 1581–1584 (2003).

  107. 107.

    et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33–42 (2001).

  108. 108.

    , , & Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19, 749–758 (2003).

  109. 109.

    , , , & API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-κB activation. Biochem. Biophys. Res. Commun. 334, 51–60 (2005).

  110. 110.

    et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601–3609 (1999).

  111. 111.

    et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica 93, 688–696 (2008).

  112. 112.

    et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 106, 19946–19951 (2009).

  113. 113.

    et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106–110 (2006).

  114. 114.

    et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 9, 272–281 (2008).

  115. 115.

    et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation. Nat. Immunol. 15, 1079–1089 (2014).

  116. 116.

    et al. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling. Nat. Commun. 6, 8777 (2015).

  117. 117.

    et al. Malt1-induced cleavage of regnase-1 in CD4+ helper T cells regulates immune activation. Cell 153, 1036–1049 (2013).

  118. 118.

    et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9, 263–271 (2008).

  119. 119.

    et al. Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5, 276 (2014).

  120. 120.

    et al. Alternative splicing of MALT1 controls signalling and activation of CD4+ T cells. Nat. Commun. 7, 11292 (2016). This paper outlines the mechanism by which TCR-induced alternative splicing of MALT1 enhances signalling and optimal T cell activation.

  121. 121.

    et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22, 812–824 (2012).

  122. 122.

    et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825–837 (2012).

  123. 123.

    et al. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J. Immunol. 190, 2896–2903 (2013).

  124. 124.

    et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J. 33, 2765–2781 (2014).

  125. 125.

    et al. MALT1 protease activity is required for innate and adaptive immune responses. PLoS ONE 10, e0127083 (2015).

  126. 126.

    et al. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J. Immunol. 194, 3723–3734 (2015).

  127. 127.

    et al. Combined immunodeficiency associated with homozygous MALT1 mutations. J. Allergy Clin. Immunol. 133, 1458–1462.e7 (2014).

  128. 128.

    et al. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation. J. Clin. Immunol. 35, 135–146 (2015).

  129. 129.

    , & Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669–682 (2015).

  130. 130.

    et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).

  131. 131.

    & Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239–252 (2009).

  132. 132.

    , & Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30–38 (2009).

  133. 133.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  134. 134.

    & Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochim. Biophys. Acta 1776, 160–174 (2007).

  135. 135.

    et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004).

  136. 136.

    Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).

  137. 137.

    et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).

  138. 138.

    , , & Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842–857 (2013).

  139. 139.

    et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527–552 (2001).

  140. 140.

    et al. The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front. Immunol. 3, 190 (2012).

  141. 141.

    & Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J. Mol. Med. (Berl.) 91, 147–155 (2013).

  142. 142.

    , , , & Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4, 172–181 (2014).

  143. 143.

    et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74, 3652–3658 (2014).

  144. 144.

    et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 3, 506–517 (2015). This paper demonstrates that CD73, a 5′-nucleoside that generates immunosuppressive adenosine in the TME, limits the efficacy of PD1 blockade. The combination of PD1 inhibition and an A2AR inhibitor increases the expression of IFNγ and granzyme B by tumor-infiltrating CD8+ T cells and significantly reduces tumour growth.

  145. 145.

    & Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res. 74, 7239–7249 (2014).

  146. 146.

    Metabolic immune checkpoint: adenosine in tumor microenvironment. Front. Immunol. 7, 109 (2016).

  147. 147.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  148. 148.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  149. 149.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  150. 150.

    & IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774 (2004).

  151. 151.

    et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11, 6030–6039 (2005).

  152. 152.

    et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).

  153. 153.

    et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).

  154. 154.

    & Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462–472 (2015).

  155. 155.

    , , , & Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int. J. Cancer 123, 780–786 (2008).

  156. 156.

    , , & Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15–24 (2008).

  157. 157.

    , , , & Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389–1402 (2013).

  158. 158.

    et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264–1272 (2013).

  159. 159.

    et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014).

  160. 160.

    et al. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin. Cancer Res. (2016).

  161. 161.

    et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016). This paper demonstrates that, in a mouse model of gliobastoma, acquired resistance to M-CSFR inhibition is associated with elevated PI3K activity driven by macrophage-derived IGF1. Resistance can be overcome by combining M-CSFR inhibitors with IGF1R or PI3K blockade.

  162. 162.

    et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest. New Drugs 31, 760–768 (2013).

  163. 163.

    et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 71, 1041–1050 (2013).

  164. 164.

    et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target. Oncol. 10, 111–123 (2015).

  165. 165.

    et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130–133 (2014).

  166. 166.

    et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).

  167. 167.

    et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).

  168. 168.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  169. 169.

    et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).

  170. 170.

    & Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427 (2011).

  171. 171.

    et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145–147 (2004).

  172. 172.

    et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 129, 507–512 (2011).

  173. 173.

    et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol. Immunother. 64, 1241–1250 (2015).

  174. 174.

    et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115–1124 (2008).

  175. 175.

    et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107, 67–74 (2006).

  176. 176.

    et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632–642 (2014).

  177. 177.

    et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinb or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32, abstr. 5010 (2014).

  178. 178.

    et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 33, abstr. 410 (2015).

  179. 179.

    et al. Safety and efficacy of MPDL328OA (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 33, abstr. 704 (2015).

  180. 180.

    & Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 13, 328–341 (2013).

  181. 181.

    , & TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220–227 (2010).

  182. 182.

    & Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790–811 (2012).

  183. 183.

    Reversal of tumor-induced immunosuppression by TGF-β inhibitors. Invest. New Drugs 21, 21–32 (2003).

  184. 184.

    et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-β (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9, e90353 (2014).

  185. 185.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  186. 186.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  187. 187.

    , , , & HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin. Cancer Res. 17, 472–482 (2011).

  188. 188.

    et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 108, 218–227 (2006).

  189. 189.

    et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 99, 1078–1087 (2014).

  190. 190.

    et al. Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741–754 (2011).

  191. 191.

    et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol. Res. 3, 1082–1095 (2015).

  192. 192.

    , & Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015). This paper demonstrates an association between activation of the WNT–β-catenin signalling pathway and the lack of a T cell gene expression signature in human samples of metastatic melanoma. Using mouse tumour models, the authors illustrate a mechanism by which tumour cell-autonomous active β-catenin signalling blocks TILs, promoting resistance to anti-PDL1 and anti-CTLA4 therapy.

  193. 193.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  194. 194.

    , , , & Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015).

  195. 195.

    et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343–354 (2016).

  196. 196.

    et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046–2054 (2012).

  197. 197.

    et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75–83 (2013).

  198. 198.

    et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521, 94–98 (2015).

  199. 199.

    et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016). This paper demonstrates that in previously untreated patients with advanced NSCLC and expression of PDL1 on at least 50% of their tumour cells, PD1 blockade was associated with a significant improvement in efficacy and reduced adverse events relative to standard-of-care chemotherapy.

  200. 200.

    et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).

  201. 201.

    , , & Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13, 516–524 (2016).

  202. 202.

    , , , & An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365–372 (2013).

  203. 203.

    et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 5, 404–407 (2012).

  204. 204.

    et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).

  205. 205.

    et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).

  206. 206.

    et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894 (2015).

  207. 207.

    et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013). This paper examines biopsies from patients with metastatic melanoma treated with a BRAF inhibitor (vemurafenib) either alone or in combination with a MEK inhibitor (dabrafenib plus trametinib) and demonstrates that either treatment results in increased expression of melanoma antigens, increased CD8+ T cell infiltrate and a decrease in immunosuppressive cytokines, consistent with a more favourable antitumour immune environment.

  208. 208.

    et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl Med. 7, 279ra41 (2015). This paper reports that the triple combination of BRAF, MEK and PD1 inhibition demonstrates superior antitumour efficacy in a mouse model of BRAF-V600E-driven melanoma, supporting the use of this therapeutic combination in the clinic.

  209. 209.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  210. 210.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  211. 211.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  212. 212.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  213. 213.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  214. 214.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  215. 215.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  216. 216.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  217. 217.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  218. 218.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  219. 219.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  220. 220.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  221. 221.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  222. 222.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  223. 223.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  224. 224.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  225. 225.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  226. 226.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  227. 227.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  228. 228.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  229. 229.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  230. 230.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  231. 231.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  232. 232.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  233. 233.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  234. 234.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  235. 235.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  236. 236.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  237. 237.

    US National Library of Medicine. ClinicalTrials.gov (2017).

Download references

Author information

Affiliations

  1. Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research.

    • Philip Gotwals
    • , Daniela Cipolletta
    • , Viviana Cremasco
    • , Britta Mueller
    • , Catherine Sabatos-Peyton
    •  & Glenn Dranoff
  2. Translational Clinical Oncology, Novartis Institutes for BioMedical Research.

    • Scott Cameron
    • , Adam Crystal
    • , Becker Hewes
    • , Sonia Quaratino
    •  & Lilli Petruzzelli
  3. Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

    • Jeffrey A. Engelman

Authors

  1. Search for Philip Gotwals in:

  2. Search for Scott Cameron in:

  3. Search for Daniela Cipolletta in:

  4. Search for Viviana Cremasco in:

  5. Search for Adam Crystal in:

  6. Search for Becker Hewes in:

  7. Search for Britta Mueller in:

  8. Search for Sonia Quaratino in:

  9. Search for Catherine Sabatos-Peyton in:

  10. Search for Lilli Petruzzelli in:

  11. Search for Jeffrey A. Engelman in:

  12. Search for Glenn Dranoff in:

Competing interests

All authors are employees and shareholders of Novartis.

Corresponding author

Correspondence to Glenn Dranoff.

Glossary

Immune checkpoint inhibitors

Therapeutic agents that reverse, for example, programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-mediated repression of cytotoxic T cell activity to enable an antitumour immune response.

Innate immune responses

Refers to the nonspecific immune defence mechanisms that identify and eliminate foreign pathogens. Cells of the innate immune response include natural killer cells, mast cells, eosinophils, basophils and phagocytic cells such as macrophages.

Dendritic cells

(DCs). Immune cells that process and display antigenic proteins in conjunction with major histocompatibility complex proteins on their surface to T cells and are the most potent antigen-presenting cells, regulating both protective immunity and tolerance.

Natural killer (NK) cells

Immune cells that can bind to and kill virally infected cells or tumour cells in the absence of antigen stimulation.

Tumour-immunity cycle

Refers to the sequence of events — tumour-associated antigen loading and activation of dendritic cells (DCs), antigen presentation by DCs to CD8+ T cells and T cell-directed cytolysis of tumours — that are required to drive a potent antitumour response.

Type I interferon

A class of secreted proteins that induce cell-intrinsic antiviral pathways, modulate the innate immune response to promote antigen presentation and natural killer cell function and promote the development of antigen-specific (adaptive) T and B cell memory responses.

Myeloid-derived suppressor cells

(MDSCs). A heterogeneous population of cells of the myeloid lineage that can potently suppress T effector cell responses and function.

T regulatory (Treg) cells

A subpopulation of T cells that help to maintain tolerance by suppressing the induction, proliferation and activity of T effector cells.

Actinic keratosis

Refers to a rough or scaly skin lesion typically associated with sun exposure.

Endogenous retroviruses

(ERVs). Genomic viral elements that are derived from or resemble exogenous retroviruses. ERVs have been implicated in some cancers and autoimmune diseases.

T cell exhaustion

A state of T cell dysfunction characterized by diminished effector functions and sustained expression of inhibitory receptors that is associated with chronic infection and cancer.

Humoral immunity

The component of the adaptive immune response that is driven by B cell activation (with the help of CD4+ T cells), which results in the secretion of antibodies from plasma cells. It also broadly refers to secreted or soluble factors that are part of an immune response, including complement.

X-linked agammaglobulinaemia

A heritable immunodeficiency caused by a mutation in Bruton tyrosine kinase (BTK) in which patients do not generate mature B cells and hence do not make antibodies.

Waldenström macroglobulinaemia

A type of non-Hodgkin lymphoma characterized by lymphoplasmacytoid cells that secrete large amounts of monoclonal antibodies known as macroglobulin.

TH1 cells

(T helper 1 cells). An effector population of activated, differentiated CD4+ T cells characterized by the secretion of inflammatory cytokines interferon-γ and tumour necrosis factor, as well as interleukin-2.

TH17 cell

(T helper 17 cell). A type of activated CD4+ T cell that promotes neutrophil activation, immunity to pathogens and inflammation.

Immunogenic cell death

(ICD). A form of cell death that is characterized by the release of damage-associated molecular patterns (DAMPs) and results in an immunostimulatory response.

Damage-associated molecular patterns

(DAMPs). Refers to host-derived molecules such as calreticulin, high mobility group box 1 protein (HMGB1), heat shock proteins, ATP and DNA that initiate and maintain an inflammatory response.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc.2017.17

Further reading